Compare · MMM vs QNRX
MMM vs QNRX
Side-by-side comparison of 3M Company (MMM) and Quoin Pharmaceuticals Ltd. (QNRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MMM and QNRX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MMM is the larger of the two at $87.80B, about 6714.9x QNRX ($13.1M).
- QNRX has been more active in the news (7 items in the past 4 weeks vs 5 for MMM).
- MMM has more recent analyst coverage (25 ratings vs 0 for QNRX).
- Company
- 3M Company
- Quoin Pharmaceuticals Ltd.
- Price
- $170.26-0.93%
- $6.54+2.75%
- Market cap
- $87.80B
- $13.1M
- 1M return
- -3.94%
- -
- 1Y return
- +10.39%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 5
- 7
- Recent ratings
- 25
- 0
3M Company
3M Company develops, manufactures, and markets various products worldwide. It operates through four business segments: Safety and Industrial, Transportation and Electronics, Health Care, and Consumer. The Safety and Industrial segment offers personal safety products, industrial adhesives and tapes, abrasives, closure and masking systems, electrical markets, automotive aftermarket, and roofing granules to industrial, electrical, and safety markets. The Transportation and Electronics provides electronics, such as display materials and systems, electronic materials solutions; automotive and aerospace, and commercial solutions; advanced materials; and transportation safety products to transportation and electronic original equipment manufacturer customers. The Health Care segment offers medical and surgical supplies, skin health and infection prevention products, oral care, separation and purification sciences, health information systems, drug delivery systems, and food safety products to healthcare industry. The Consumer segment provides home improvement, home care, and consumer health care products, as well as stationery and office supplies to various consumers. This segment is also involved in the retail auto care business. It offers its products through various e-commerce and traditional wholesalers, retailers, jobbers, distributors, and dealers, as well as directly to users. 3M Company has a strategic collaboration with Merry Maids in residential cleaning sector; and collaborations with The Infectious Disease Research Institute and Duke Human Vaccine Institute to create a vaccine candidate with potential to provide protection against multiple variants of SARS-CoV-2. The company was founded in 1902 and is headquartered in St. Paul, Minnesota.
Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
Latest MMM
- 3M Announces Upcoming Investor Event
- 3M Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation
- SEC Form 3 filed by new insider George Bobby K
- SEC Form 3 filed by new insider Cunningham Jennifer A.
- 3M Board Declares Quarterly Dividend
- Group President Chavez Rodriguez Beatriz Karina sold $663,430 worth of shares (3,635 units at $182.51), decreasing direct ownership by 21% to 14,035 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by 3M Company
- Sr Vice President & CAO Reinseth Theresa E sold $156,544 worth of shares (924 units at $169.42), decreasing direct ownership by 26% to 2,615 units (SEC Form 4)
- Executive Vice President Banovetz John Patrick exercised 7,880 shares at a strike of $154.69 and sold $1,343,067 worth of shares (7,880 units at $170.44) (SEC Form 4)
- EVP, Chief Legal Off & Secret Rhodes Kevin H exercised 7,669 shares at a strike of $154.69 and sold $1,312,933 worth of shares (7,669 units at $171.20) (SEC Form 4)
Latest QNRX
- Director Langer Dennis was granted 34,534 units of ADSs, increasing direct ownership by 159% to 56,243 units (SEC Form 4)
- Director Culverwell Anthony James was granted 31,352 units of ADSs, increasing direct ownership by 1,094% to 34,218 units (SEC Form 4)
- Quoin Pharmaceuticals Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome
- Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million
- Quoin Pharmaceuticals Ltd. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events
- Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results
- Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026
- SEC Form DEF 14A filed by Quoin Pharmaceuticals Ltd.
- Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome